Clinical and pathologic relevance of p53 index in canine osseous tumors

Veterinary Pathology

Volumn 40, Issue 3, 2003, Pages 237-248

  Loukopoulos, P ^a,b   Thornton, J R ^a   Robinson, W F ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Bone diseases; Dogs; Immunohistochemistry; Neoplasms; Osseous tumors; Osteosarcoma; p53

Indexed keywords

PROTEIN P53;

ANIMAL TISSUE; ARTICLE; AUTOPSY; BIOPSY; BONE TUMOR; BREED; CANCER SUSCEPTIBILITY; CHONDROSARCOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ERROR; DISEASE ASSOCIATION; DISEASE SEVERITY; DOG; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MITOSIS; NONHUMAN; OSTEOSARCOMA; PARAMETER; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SAMPLE; SARCOMA; SCORING SYSTEM; TUMOR CELL; TUMOR LOCALIZATION; TUMOR NECROSIS; ANIMAL; ANIMAL DISEASE; DOG DISEASE; FEMALE; METABOLISM; MITOSIS INDEX; PATHOLOGY; RETROSPECTIVE STUDY;

ANIMALIA; CANIS FAMILIARIS;

ANIMALS; BONE NEOPLASMS; DOG DISEASES; DOGS; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; MITOTIC INDEX; OSTEOSARCOMA; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0038486965     PISSN: 03009858     EISSN: None     Source Type: Journal    
DOI: 10.1354/vp.40-3-237     Document Type: Article

References (121)

1. Backe J, Gassel AM, Hauber K: p53 protein in endometrial cancer is related to proliferative activity and prognosis but not to expression of p21 protein. Int J Gynecol Pathol 16:361-368, 1997
2. Barrett J: Immunohistochemical study of cytoskeletal filaments in spindle cell tumors of the dog (Canis familiaris). MVSc Thesis, University of Queensland, Brisbane, Australia, 1998
3. Bartek J, Iggo R, Gannon J: Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 5:893-899, 1990
4. Bergman PJ, MacEwen EG, Kurzman ID: Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). J Vet Intern Med 10:76-81, 1996
5. Bodey B, Groger AM, Bodey BJ: Immunohistochemical detection of p53 protein overexpression in primary human osteosarcomas. Anticancer Res 17:493-498, 1999
6. Brennan JA, Mao L, Hruban RH: Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 332:429-435, 1995
7. Brodey RS, McGrath JT, Reynolds H: A clinical and radiological study of canine bone neoplasms: part I. J Am Vet Med Assoc 134:53-71, 1959
8. Brodey RS, Riser WH: Canine osteosarcoma. A clinicopathologic study of 194 cases. Clin Orthop 62:54-64, 1969
9. Brodey RS, Sauer RM, Medway W: Canine bone neoplasms. J Am Vet Med Assoc 143:471-495, 1963
10. Carson DA, Lois A: Cancer progression and p53. Lancet 346:1009-1011, 1995
11. Cheng L, Leibovich BC, Bostwick DG: p53 alteration in regional lymph node metastases from prostate carcinoma: a marker of disease progression. Cancer 85: 2455, 1999
12. Cheng L, Sebo TJ, Bostwick DG: p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy. Cancer 85:1293, 1999
13. Chiarugi V, Magnelli L, Cinelli M: Oncogenes, p53, and tumor angiogenesis. J Cancer Res Clin Oncol 124: 523-525, 1998
14. Chu LL, Rutteman GR, Kong JM: Genomic organization of the canine p53 gene and its mutational status in canine mammary neoplasia. Breast Cancer Res Treat 50:11-25, 1998
15. Cohen D, Reif JS, Brodey RS: Epidemiological analysis of the most prevalent sites and types of canine neoplasia observed in a veterinary hospital. Cancer Res 34:2859-2868, 1974
16. Coomber BL, Denton J, Sylvestre A: Blood vessel density in canine osteosarcoma. Can J Vet Res 62:199-204, 1998
17. Cotchin E: Spontaneous sarcomas of bone in dogs. Br Vet J 109:248-257, 1953
18. de Krijger RR, van der Harst E, Bosman FT: Prognostic value of p53, bcl-2 and c-erbB-2 protein expression. J Pathol 188:51, 1999
19. Devilee P, Van Leeuwen IS, Voesten A: The canine p53 gene is subject to somatic mutations in thyroid carcinoma. Anticancer Res 14:2039-2046, 1994
20. Dong Y, Walsh MD, McGuckin MA: Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer. Int J Cancer 74:407-415, 1997
21. Ehrhart N, Dernell WS, Hoffmann WE: Prognostic importance of alkaline phosphatase activity in serum from dogs with appendicular osteosarcoma: 75 cases (1990-1996). J Am Vet Med Assoc 213:1002-1006, 1998
22. Ellis PA, Lonning PE, Borresen-Dale A: Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. Br J Cancer 76:480-485, 1997
23. Ellison DW, Steart PV, Bateman AC: Prognostic indicators in a range of astrocytic tumors: an immunohistochemical study with Ki-67 and p53 antibodies. J Neurol Neurosurg Psychiatry 59:413-419, 1995
24. Esrig D, Elmajian D, Groshen S: Accumulation of nuclear p53 and progression in bladder cancer. N Engl J Med 331:1259-1264, 1994
25. Esrig D, Spruck CH, Nichols PW: p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 143:1389-1397, 1993
26. Finlay CA, Hinds PW, Tan TH: Activating mutations for transformation by p53 produce a gene product that forms an hsc-70-p53 complex with an altered half life. Mol Cell Biol 8:531-539, 1988
27. Forrest LJ, Dodge RK, Page RL: Relationship between quantitative tumor scintigraphy and time to metastasis in dogs with osteosarcoma. J Nucl Med 33:1542-1547, 1992
28. Furihata M, Sonobe H, Ohtsuki Y: The aberrant p53 protein. Int J Oncol 6:1209-1226, 1995 [Review]
29. Gamblin RM, Sagartz JE, Couto CG: Overexpression of p53 tumor suppressor protein in spontaneously arising neoplasms of dogs. Am J Vet Res 58:857-863, 1997
30. Gao J, Schwalb TA, Addeo JV: The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca: the effect of topical cyclosporin a therapy. Cornea 17: 654-663, 1998
31. Garzotto CK, Berg J, Hoffmann WE: Prognostic significance of serum alkaline phosphatase activity in canine appendicular osteosarcoma. J Vet Intern Med 14: 587-592, 2000
32. Giatromanolaki A, Stathopoulos GP, Koukourakis MI: Combined role of tumor angiogensis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma. Cancer 86:1421, 1999
33. Ginn PE, Fox LE, Brower JC: Immunohistochemical detection of p53 tumor-suppressor protein is a poor indicator of prognosis for canine cutaneous mast cell tumors. Vet Pathol 37:33-39, 2000
34. Girlando S, Slomp P, Caffo O: p21 expression in colorectal carcinomas: a study on 103 cases with analysis of p53 gene mutation/expression and clinic-pathological correlations. Virchows Arch 435:559-565, 1999
35. Greenblatt M, Bennett W, Hollstein M: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878, 1994
36. Guevara-Fujita M, Loechel R, Venta P: Chromosomal assignment of seven genes on canine chromosomes by fluorescence in situ hybridization. Mamm Genome 7: 268-270, 1996
37. Hainaut P, Hernandez T, Robinson A: IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucl Acids Res 26:1998, 1998
38. Hammer AS, Weeren FR, Weisbrode SE: Prognostic factors in dogs with osteosarcomas of the flat or irregular bones. J Am Anim Hosp Assoc 31:321-326, 1995
39. Hernandez T, Hainaut P, Montesano R: The IARC Database of somatic p53 mutations in human tumors and cell lines. http://www.iarc.fr/p53/, International Agency for Research on Cancer, 2000.
40. Hollstein M, Sidransky D, Vogelstein B: p53 mutations in human cancers. Science 253:49-53, 1991
41. Hurlimann J, Chaubert P, Benhattar J: p53 gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniques. Mod Pathol 7:423-428, 1994
42. Hwang J-K, Lin C-T: Co-localization of endogenous and exogenous p53 proteins in nasopharyngeal carcinoma cells. J Histochem Cytochem 45:991-1003, 1997
43. Igarashi N, Takahashi M, Fujimoto S: Predictive value of Ki-67, p53 protein, and DNA content in the diagnosis of gastric carcinoma. Cancer 86:1449, 1999
44. Iggo R, Gatter K, Bartek J: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335:675-679, 1990
45. Ikeda G, Isaji S, Kawarada Y: Prognostic significance of biologic factors in squamous cell carcinoma of the esophagus. Cancer 86:1396, 1999
46. Inoue M, Shiramizu K: Immunohistochemical detection of p53 and c-myc proteins in canine mammary tumors. J Comp Pathol 120:169-175, 1999
47. Inoue M, Wada N: Immunohistochemical detection of p53 and p21 proteins in canine testicular tumors. Vet Rec 146:370-372, 2000
48. Ioachim E, Goussia A, Agnantis NJ: Glycoprotein CD44 expression in colorectal neoplasms. An immunohistochemical study including correlation with cathepsin D, extracellular matrix components, p53, Rb, bcl-2, c-erbB-2, EGFR and proliferation indices. Virchows Arch 434:45-50, 1999
49. Jaffe MH, Hosgood G, Taylor HW: Immunohistochemical and clinical evaluation of p53 in canine cutaneous mast cell tumors. Vet Pathol 37:40-46, 2000
50. Johnson SA, Couto CG, Weghorst CM: Mutation of the p53 tumor suppressor gene in spontaneously occurring osteosarcomas of the dog. Carcinogenesis 19:213-217, 1998
51. Johnston HM, Thompson H, Pirie HM: p53 immunohistochemistry in domestic animal tumors. Eur J Vet Pathol 2:135-140, 1996
52. Kahlenberg MS, Stoler DL, Petrelli NJ: p53 tumor suppressor gene mutations predict decreased survival of patients with sporadic colorectal carcinoma. Cancer 88: 1814, 2000
53. Kaklamanis L, Gatter KC, Mortensen N: p53 expression in colorectal adenomas. Am J Pathol 142:87-93, 1993
54. Karamitopoulou E, Perentes E, Diamantis I: p53 protein expression in colorectal adenomas: an immunohistochemical study using an antigen retrieval system. Histopathology 27:517-523, 1995
55. Kaserer K, Schmaus J, Wrba F: Staining patterns of p53 immunohistochemistry and their biological significance in colorectal cancer. J Pathol 190:450, 2000
56. Kirpensteijn J: Clinical and pathogenetic studies in canine osteosarcoma. PhD Thesis, Universiteit Utrecht, Utrecht, The Netherlands, 1999
57. Lane DP: P53, guardian of the genome. Nature 358: 15-16, 1992
58. Lane DP, Crawford LV: T antigen is bound to a host protein in SV 40-transformed cells. Nature 278:261-263, 1979
59. Levine RA, Fleischli MA: Inactivation of p53 and retinoblastoma family pathways in canine osteosarcoma cell lines. Vet Pathol 37:54-61, 2000
60. Liang S-B, Ohtsuki Y, Furihata M: Sun-exposure and aging-dependent p53 protein accumulation results in growth advantage for tumor cells in carcinogenesis of nonmelanocytic skin cancer. Virchows Arch 434:193-199, 1999
61. Ling GV, Morgan JP, Pool RR: Primary bone tumors in the dog: a combined clinical, radiographic, and histologic approach to early diagnosis. J Am Vet Med Assoc 165:55-67, 1974
62. Lipponen P, Eskelinen M, Hietala K: Expression of proliferating cell nuclear antigen (PC10), p53 protein and c-erbb-2 in renal adenocarcinoma. Int J Cancer 57:275-280, 1994
63. Liu S-K, Dorfman H, Hurvitz A: Primary and secondary bone tumors in the dog. J Small Anim Pract 18: 313-326, 1977
64. Lonardo V, Takafumi U, Huvos AG: p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate. Cancer 79: 1541-1547, 1997
65. Luo J, Su F, Chen D: Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408:377-381, 2000
66. Ma L, Ronai A, Riede U: Clinical implication of screening p53 gene mutations in head and neck squamous cell carcinomas. J Cancer Res Clin Oncol 124: 389-396, 1998
67. Malof FR: P53 presentation and other prognostic indicators in oral squamous cell carcinoma. MDSc Thesis, University of Sydney, Sydney, Australia, 1996
68. Mansoor A, McKee PH, Simpson JA: Prognostic significance of Ki-67 and p53 immunoreactivity in cutaneous squamous cell carcinomas. Am J Dermatopathol 18:351-357, 1996
69. Mayr B, Dressler A, Reifinger M: Cytogenetic alterations in eight mammary tumors and tumor-suppressor gene p53 mutation in one mammary tumor from dogs. Am J Vet Res 59:69-78, 1998
70. Mayr B, Loupal G, Schleger W: Genetic alterations in four cases of canine mammary tumors: two trisomies, translocations and one tumor suppressor gene p53 mutation. Arch Zootec 45:315-321, 1996
71. Mayr B, Reifinger M, Alton K: Novel canine tumor suppressor gene p53 mutations in cases of skin and mammary neoplasms. Vet Res Commun 23:285-291, 1999
72. Mayr B, Reifinger M, Brem G: Cytogenetic, ras, and p53: studies in cases of canine neoplasms (hemangiopericytoma, mastocytoma, histiocytoma, chloroma). J Hered 90:124-128, 1999
73. Mayr B, Schaffner W, Botto I: Canine tumor suppressor gene p53-mutation in a case of adenoma of circumanal glands. Vet Res Commun 21:369-373, 1997
74. McEntee MF, Brenneman KA: Dysregulation of beta-catenin is common in canine sporadic colorectal tumors. Vet Pathol 36:228-236, 1999
75. Mendoza S, Konishi T, Dernell WS: Status of the p53, Rb and MDM2 genes in canine osteosarcoma. Anticancer Res 18:4449-4453, 1998
76. Misdorp W, Hart AA: Some prognostic and epidemiologic factors in canine osteosarcoma. J Natl Cancer Inst 62:537-545, 1979
77. Montenarh M: Biochemical properties of the growth suppressor/oncoprotein p53. Oncogene 7:1673-1680, 1992
78. Mukhopadhyay T, Maxwell SA, Roth JA: p53 Suppressor Gene, 1st ed., pp. 1-129. Springer-Verlag, New York, 1995
79. Muto T, Wakui S, Takahashi H: p53 gene mutations occurring in spontaneous benign and malignant mammary tumors of the dog. Vet Pathol 37:248-253, 2000
80. Nakopoulou LL, Alexiadou A, Theodoropoulos GE: Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer. J Pathol 179:31-38, 1996
81. Nasir L, Argyle DJ: Mutational analysis of the tumor suppressor gene p53 in lymphosarcoma in two bull mastiffs. Vet Rec 145:23-24, 1999
82. Nasir L, Argyle DJ, McFarlane ST: Nucleotide sequence of a highly conserved region of the canine p53 tumor suppressor gene. DNA Seq 8:83-86, 1997
83. Nieder C, Petersen S, Thames HD: The challenge of p53 as prognostic and predictive factor in gliomas. Cancer Treat Rev 26:67, 2000
84. Palmer N: X. Neoplastic and tumorous conditions of bones. In: Pathology of Domestic Animals, ed. Jubb KVF, Kennedy PC, Palmer N, 4th ed., pp. 125-138. Academic Press, San Diego, CA, 1993
85. Park SH, Kim YI, Park YH: Clinicopathologic correlation of p53 protein overexpression in adenoma and carcinoma of the ampulla of Vater. World J Surg 24: 54-59, 2000
86. Peller S: Clinical implications of p53: effect on prognosis, tumor progression and chemotherapy response. Semin Cancer Biol 8:379, 1998
87. Pietenpol JA, Vogelstein B: No room at the p53 inn. Nature 365:17-18, 1993
88. Pileri S, Roncador G, Ceccarelli C: Antigen retrieval techniques in immunohistochemistry: comparison of different methods. J Pathol 183:116-123, 1997
89. Powers BE, Withrow SJ, Thrall DE: Percent tumor necrosis as a predictor of treatment response in canine osteosarcoma. Cancer 67:126-134, 1991
90. Ru G, Terracini B, Glickman L: Host related risk factors for canine osteosarcoma. Vet J 156:31-39, 1998
91. Rungsipipat A, Tateyama S, Yamaguchi R: Immunohistochemical analysis of c-yes and c-erbB-2 oncogene products and p53 tumor suppressor protein in canine mammary tumors. J Vet Med Sci 61:27-32, 1999
92. Sagartz JE, Bodley WL, Gamblin RM: p53 tumor suppressor protein overexpression in osteogenic tumors of dogs. Vet Pathol 33:213-221, 1996
93. Salnikow K, Costa M, Blagosklonny MV: Hyperinducibility of hypoxia-responsive genes without p53/p21 dependent checkpoint in aggressive prostate cancer. Cancer Res 60:5630, 2000
94. Schneider-Stock R, Onnasch D, Haeckel C: Prognostic significance of p53 gene mutations and p53 protein expression in synovial sarcomas. Virchows Arch 435: 407-412, 1999
95. Setala L, Kosma V-M, Lipponen P: Clinical relevance of p53 index and expression of proliferating cell nuclear antigen and Ki-67 in gastric cancer. J Cancer Res Clin Oncol 124:497-502, 1998
96. Shahin MS, Hughes JH, Buller RE: The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 89:2006, 2000
97. Shiina H, Igawa M, Nagasaki M: Clinical significance of mdm2 and p53 expression in bladder cancer. Oncology 56:239, 1999
98. Slayter MV, Boosinger TR, Pool RR: Histological Classification of Bone and Joint Tumors of Domestic Animals, vol. 1, pp. 1-50. Armed Forces Institute of Pathology, Washington, DC, 1994
99. Soussi T, Legros Y, Lubin R: Multifactorial analysis of p53 alteration in human cancer. Int J Cancer 57:1-9, 1994 [Review]
100. Spodnick GJ, Berg J, Rand WM: Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978-1988). J Am Vet Med Assoc 200:995-999, 1992
101. Straw RC: Bone and joint tumors. In: Textbook of Veterinary Internal Medicine: Diseases of the Dog and Cat, ed. Ettinger SJ, Feldman EC, 5th ed., pp. 535-540. WB Saunders, Philadelphia, PA, 2000
102. Straw RC, Powers BE, Klausner J: Canine mandibular osteosarcoma: 51 cases (1980-1992). J Am Anim Hosp Assoc 32:257-262, 1996
103. Straw RC, Withrow SJ, Powers BE: Management of canine appendicular osteosarcoma. Vet Clin North Am Small Anim Pract 20:1141-1161, 1990
104. Straw RC, Withrow SJ, Richter SL: Amputation and cisplatin for treatment of canine osteosarcoma. J Vet Intern Med 5:205-210, 1991
105. Sun Y, Nakamura K, Wendel E: Progression toward tumor cell phenotype is enhanced by overexpression of a mutant p53 tumor suppressor gene isolated from nasopharyngeal carcinoma. Proc Natl Acad Sci USA 90: 2827-2831, 1993
106. Sylvestre A, Brash M, Atilola M: A case series of 25 dogs with chondrosarcoma. Vet Comp Orthop Traumatol 5:13-17, 1992
107. Teifke JP, Löhr CV: Immunohistochemical detection of p53 overexpression in paraffin wax-embedded squamous cell carcinomas of cattle, horses, cats and dogs. J Comp Pathol 114:205-210, 1996
108. Teifke JP, Löhr CV, Shirasawa H: Detection of canine oral papillomavirus-DNA in canine oral squamous cell carcinomas and p53 overexpressing skin papillomas of the dog using the polymerase chain reaction and non-radioactive in situ hybridization. Vet Microbiol 60:119-130, 1998
109. Tjalma RA: Canine bone sarcoma: estimation of relative risk as a function of body size. J Natl Cancer Inst 36:1137-1150, 1966
110. Van Leeuwen IS, Cornelisse CJ, Misdorp W: P53 gene mutations in osteosarcomas in the dog. Cancer Lett 111:173-178, 1997
111. Van Leeuwen IS, Hellmen E, Cornelisse CJ: p53 mutations in mammary tumor cell lines and corresponding tumor tissues in the dog. Anticancer Res 16:3737-3740, 1996
112. Veldhoen N, Milner J: Isolation of canine p53 cDNA and detailed characterization of the full length canine p53 protein. Oncogene 16:1077-1084, 1998
113. Veldhoen N, Stewart J, Brown R, Milner J: Mutations of the p53 gene in canine lymphoma and evidence for germ line p53 mutations in the dog. Oncogene 16:249-255, 1998
114. Veldhoen N, Watterson J, Brash M: Identification of tumor-associated and germ line p53 mutations in canine mammary cancer. Br J Cancer 81:409-415, 1999
115. Vesalainen SLB, Lipponen PK, Talja MT: Proliferating cell nuclear antigen and p53 expression as prognostic factors in T1-2m0 prostatic adenocarcinoma. Int J Cancer 58:303-308, 1994
116. Vitellozzi G, Mariotti F, Ricci G: Immunohistochemical expression of the p53 protein in testicular tumors in the dog. Eur J Vet Pathol 4:61-65, 1998
117. Warnakulasuriya S, Jia C, Houghton J: p53 and P-glycoprotein expression are significant prognostic markers in advanced head and neck cancer treated with chemo/ radiotherapy. J Pathol 191:33, 2000
118. Waters DJ, Cooley DM: Skeletal neoplasms. In: Cancer in Dogs and Cats. Medical and Surgical Management, ed. Morrison WB, 1st ed., pp. 639-654. Williams and Wilkins, Baltimore, MD, 1998
119. Webb PM, Green A, Cummings MC: Relationship between number of ovulatory cycles and accumulation of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst 90:1729-1734, 1998
120. Wolf JC, Ginn PE, Homer B: Immunohistochemical detection of p53 tumor suppressor gene protein in canine epithelial colorectal tumors. Vet Pathol 34:394-404, 1997
121. Xie X, Clausen OPF, Boysen M: The prognostic value of spontaneous apoptosis, Bax, Bcl-2 and p53 in oral squamous cell carcinoma of the tongue. Cancer 86:913, 1999